About the Company
We do not have any company description for PROKIDNEY CORP. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on PROKIDNEY CORP.
ProKidney Corp. CEO to Present at 43rd Annual J.P. Morgan ... - Nasdaq
ProKidney Corp., a late clinical-stage biotech company specializing in cell therapy for chronic kidney disease (CKD), announced that its CEO, Bruce Culleton, M.D., will present at the 43rd Annual ...
ProKidney Corp. Reports Q2 2025 Financial Results
Prokidney Corp. ( ($PROK) ) has released its Q2 earnings. Here is a breakdown of the information Prokidney Corp. presented to its investors.
ProKidney Corp. Announces FDA Alignment on Accelerated ... - Nasdaq
ProKidney Corp. Announces FDA Alignment on Accelerated Approval Pathway for Rilparencel in Chronic Kidney Disease and Diabetes July 15, 2025 — 07:42 am EDT Written by None for Quiver Quantitative -> ...
ProKidney reports larger second-quarter loss as key studies continue
ProKidney has expanded from 80 to more than 200 employees over the past three years. The company said it is hiring in the ...
ProKidney’s Future Promising: REACT Trial Success and Strategic ...
The associated price target is $6.00. Justin Zelin’s Buy rating for ProKidney’s stock is majorly influenced by a series of factors that are promising for the company’s future.
ProKidney and Social Capital Suvretta Holdings Corp. III (“SCS”) to ...
On January 18, 2022, ProKidney announced that it would become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III (Nasdaq: DNAC).
2023-11-13 | NDAQ:PROK | Press Release | ProKidney Corp - Stockhouse
WINSTON-SALEM, N.C., Nov. 13, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on ...
ProKidney Corp.'s (NASDAQ:PROK) top owners are retail investors with 32 ...
To get a sense of who is truly in control of ProKidney Corp. (NASDAQ:PROK), it is important to understand the ownership structure of the business. With 32% stake, retail investors possess the ...
BTIG Reaffirms Their Buy Rating on ProKidney (PROK)
In a report released on January 5, Justin Zelin from BTIG maintained a Buy rating on ProKidney (PROK – Research Report), with a price target of $6.00. The company’s shares closed last Friday ...
ProKidney Corp. (PROK) - Yahoo Finance Canada
ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024 WINSTON-SALEM, N.C ...
ProKidney Corp. (PROK) is a Great Momentum Stock: Should You Buy?
It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. ProKidney Corp. currently has a ...
ProKidney Corp. Reports Second Quarter 2022 Financial Results and ...
ProKidney completed its previously announced business combination with SCS and commenced trading of the combined company’s Class A ordinary shares on the Nasdaq Capital Market under the ticker ...
Similar Companies
Loading the latest forecasts...